Advertisement

The history of the development of minoxidil

  • Gerald R. Zins
    Correspondence
    Address for correspondence: Gerald R. Zins, PhD, The Upjohn Company, 7235-126-3, 301 Henrietta Street, Kalamazoo, MI 49007.
    Affiliations
    From the Hair Growth Research Unit, The Upjohn Company, Kalamazoo, Michigan USA
    Search for articles by this author
      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      By means of increasingly more penetrating research efforts, the pharmaceutical industry is acquiring ever greater insight into disease and other adverse processes. This results in the discovery and development of drugs with more highly complex actions. This, together with a more stringent surveillance by government regulatory agencies, has increased the time required to develop a newly discovered entity from a few years in the 1950s and early 1960s to as much as 10–12 years at the present time. In cases where serendipitous discovery of new opportunities results in added dimensions for pursuit, the time required is even greater. The development of minoxidil as an agent to reverse androgenetic alopecia, now being concluded after 27 years, characterizes this more elaborate process.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinics in Dermatology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Freyburger WA
        • Weeks JR
        • DuCharme DW
        Cardiovascular actions of the hypotensive agent, N,N-diallylmelamine (U-7720).
        Naunyn Schmiedebergs Arch Pharmacol. 1965; 251: 39-47
        • Zins GR
        The in vivo production of a potent, long-acting hypotensive metabolite from diallylmelamine.
        J Pharmacol Exp Ther. 1965; 150: 109-117
        • Zins GR
        • Ursprung JJ
        • Weeks JR
        The discovery and the sequential metabolism of a long-acting hypotensive agent.
        in: Roth LJ Isotopes in Experimental Pharmacology. University of Chicago, Chicago1965: 361-382
        • Zins GR
        • Emmert DE
        • Walk RA
        Hypotensive metabolite production and sequential metabolism of N,N-diallylmelamine in rats, dogs and man.
        J Pharmacol Exp Ther. 1968; 159: 194-205
        • DuCharme DW
        • Freyburger WA
        • Graham BE
        • et al.
        Pharmacologic properties of minoxidil: a new hypotensive agent.
        J Pharmacol Exp Ther. 1973; 184: 662-670
        • Carlson RG
        • Feenstra ES
        Toxicologic studies with the hypotensive agent, minoxidil.
        Toxicol Appl Pharmacol. 1977; 39: 1-11
        • Zins GR
        Alterations in renal function during vasodilator therapy.
        in: Wesson LG Fannelli GL Recent Advances in Renal Physiology and Pharmacology. University Park Press, Baltimore1974: 165-186
        • Wendung MG
        • DeGraaf GL
        • DuCharme DW
        The effects of sympatholytics, angiotensin and vasopressin on the cardiovascular response to minoxidil or hydralazine in conscious dogs.
        Clin Exp Hypertens. 1979; 1: 521-537
        • Humphrey SJ
        • Zins GR
        Whole body and regional hemodynamic effects of minoxidil in the conscious dog.
        J Cardiovasc Pharmacol. 1984; 6: 979-988
        • Gilmore E
        • Weil J
        • Chidsey C
        Treatment of essential hypertension with a new vasodilator in combination with beta-andrenergic blockade.
        N Engl J Med. 1970; 282: 521-527
        • Gottlieb TB
        • Katz FH
        • Chidsey CA
        Combined therapy with vasodilator drugs and beta-adrenergic blockade in hypertension. A comparative study of minoxidil and hydralazine.
        Circulation. 1972; 45: 571-582
        • Gottlieb TB
        • Thomas RC
        • Chidsey CA
        Pharmacokinetic studies of minoxidil.
        Clin Pharmacol Ther. 1972; 13: 436-441
        • Royer ME
        • Ko H
        • Gilbertson TJ
        • et al.
        Radioimmunoassay of minoxidil in human serum.
        J Pharm Sci. 1977; 66: 1266-1269
        • Thomas RC
        • Harpootlian H
        Metabolism of minoxidil, a new hypotensive agent II: Biotransformation following oral administation to rats, dogs, and monkeys.
        J Pharm Sci. 1975; 64: 1366-1371
        • Zins GR
        • Martin WB
        The clinical pharmacology of minoxidil.
        in: 5th ed. Excerpta Med Int Congr Ser. 496. 1980: 72-79
        • Hood B
        • Orndahl G
        • Bjork S
        Survival and mortality in malignant (grade IV) and grade III hypertension. Trends in consecutive, actively treated groups.
        Acta Med Scand. 1970; 187: 291-302
        • Breckenridge A
        • Dollery CT
        • Parry EH
        Prognosis of treated hypertension. Changes in life expectancy and causes of death between 1952 and 1967.
        Q J Med. 1970; 39: 411-429
        • Sobota JT
        • Martin WB
        • Carlson RG
        • et al.
        Minoxidil: right atrial cardiac pathology in animals and in man.
        Circulation. 1980; 62: 376-387